round button
Leave a message

中東およびアフリカの乳がん診断市場 – 2030 年までの業界動向と予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

中東およびアフリカの乳がん診断市場 – 2030 年までの業界動向と予測

  • Medical Devices
  • Published Report
  • Feb 2023
  • MEA
  • 350 ページ
  • テーブル数: 152
  • 図の数: 35

中東およびアフリカの乳がん診断市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2030
Diagram 市場規模(基準年)
USD MILLION
Diagram Market Size (Forecast Year)
USD 405.56
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

中東およびアフリカの乳がん診断市場、検査タイプ別(画像診断、生検、ゲノム検査、血液検査など)、タイプ別(乳管内癌、浸潤性乳管癌、炎症性乳がん、転移性乳がん)、エンドユーザー別(病院、診療所、研究・学術機関、診断センターなど)、流通チャネル別(直接入札、小売販売など)、2030年までの業界動向および予測。

中東およびアフリカの乳がん診断市場

中東およびアフリカの乳がん診断市場の分析と洞察

乳がんは人口の中で最も一般的な病気であり、主に増殖性疾患を持つ女性に発生します。乳がんは主に乳房組織で発生します。乳がんの症状には、乳房のしこり、乳房の大きさと形の違い、乳首からの分泌物、皮膚の炎症を起こした鱗状の赤い斑点などがあります。女性の乳がんの発生率は、薬の成長とともに乳がん市場の成長が増加するたびに増加しています。開発された技術による乳がんの診断のための高度な方法。乳がんの分野で開発された技術を改善し、有効性、精度、効率、信頼性、結果の速度を向上させ、障害の検出を改善します。より短時間でがんを検出するための高度な機能。がんは早期に検出されるため、患者の回復が早まり、がん細胞が体の他の部分に広がるのを防ぎ、市場に出回っている新しい薬で治療することができます。腫瘍のスクリーニングと画像化の増加は、乳がん市場を牽引します。これにより、乳がん市場は拡大し、毎年患者数が増加し、乳がんからの回復率も増加しています。新薬開発プロジェクトの利用可能性を高め、治療の有効性と効率性を高め、新薬を医療分野に統合することによる政府の支援。

中東およびアフリカの乳がん診断市場

中東およびアフリカの乳がん診断市場

しかし、がん診断治療のコストの高さと熟練した専門家の不足が、市場の成長を抑制している要因となっています。

Data Bridge Market Research は、中東およびアフリカの乳がん診断市場は、予測期間中に 7.1% の CAGR で成長し、2030 年までに 4 億 556 万米ドルに達すると予測しています。中東およびアフリカでは乳がん患者の増加と乳がん治療の技術的進歩により、検査タイプが市場で最大の診断タイプ セグメントを占めています。この市場レポートでは、価格分析、特許分析、技術的進歩についても詳細に取り上げています。

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2020~2016年にカスタマイズ可能)

定量単位

売上高(百万米ドル)、販売数量(個数)、価格(米ドル)

対象セグメント

By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others)  Distribution Channel (Direct Tender, Retail Sales, and Others).

Countries Covered

South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa.

Market Players Covered

The major companies which are dealing in the market are F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc., and Abacus ALS, among others.

Middle East and Africa Breast Cancer Diagnostics Market Definition

Breast cancer is a disease in which the uncontrolled growth of malignant cells in the breast tissue occurs more often in women than in men. Breast cancer is the uncontrolled cell division of breast cells, which are the most common cells in the mammary glands and ducts. Some symptoms of breast cancer include a lump or lump in the breast, bloody discharge from the nipple and a change in the shape of the nipple or breast. Breast cancer treatment depends on the stage of cancer. Its treatment consists of chemotherapy, radiation therapy, hormone therapy, and surgery.

Breast cancer is another type of cancer that is more common in women than in men. A number of the symptoms of the sickness hold bleeding secretion from the reproductive organ, a lump or block within the breast, and variations in the texture or form of the breast or nipple. Breast cancer treatment depends on the stage of cancer. In addition, its treatment includes radiotherapy, therapy, hormone therapy and surgery. Early detection of carcinoma is essential for the effective treatment of the disease. Early detection of the disease also leads to better outcomes, including many treatment options, better survival and better quality of life. Increasing pressure and demand for new forms of treatment or methods of treatment are due to the rapidly increasing spread of diseases.

Middle East and Africa Breast Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Launch of technologically advanced diagnosis & therapeutics to aid growth

Breast cancer is the most common disease in the population, occurring mainly in women with proliferative disease. Breast cancer develops in the breast tissues. Symptoms of breast cancer include lumps in the breast, differences in the size and shape of the breast, discharge from the nipples, and itchy, scaly red patches on the skin. This disease spreads in body with increasing symptoms such as bone pain, swollen lymph nodes, difficulty in breathing and many others. Increasing research and development with new technologies and treatments developed for breast cancer will significantly contribute to market growth.

Moreover, Technological advances in imaging are creating new opportunities for improvements in both screening and early detection. One technology advance is 3-D mammography, also called breast tomosynthesis. This procedure takes images from different angles around the breast and builds them into a 3-D-like image.

In the recent times, several advancements in technology is changing the fate of cancer diagnostics, as mentioned above some of the recent advancements, several other technologies are currently under trial phase which are on the limit of changing the process of breast cancer diagnostics. These technological advancements in the field are acting as a major drivers for Middle East and Africa breast cancer diagnostics market.

  • Increasing prevalence of breast cancer

One of the major factors driving the growth of the Middle East and Africa market is the increasing prevalence of breast cancer worldwide, which is expected to lead to a large number of patients in need of accurate and effective treatment options. Breast cancer is one of the most common cancers in the world, and better diagnostics are expected to increase the number of patients diagnosed in the future.

In addition, the growing demand for preventive care and early treatment has led to many cancer screenings, which would also increase the number of patients with a high need for treatment during the forecast period.

Thus, increasing prevalence of breast cancer leads to more diagnosis of cases and hence it is expected to drive the market growth during the forecast period.

Restraint

  • Adverse effects of breast cancer therapeutics

Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat. By the time symptoms appear, cancer may have begun to spread. Several screening tests are used for detecting breast cancers which include breast magnetic resonance imaging, diagnostic mammogram, biopsy etc. Although these test are considered to be standard for diagnosing breast cancer, they have their associated risks which include false-negative results, false-positive results, and side effects such as undue psychological stress, excessive radiation exposure, and a serious risk of tumor rupture and spread of cancerous cells.

Opportunity

  • Initiatives taken by the government

Government is focusing on increasing the initiative for breast cancer treatments with advanced techniques to improve the health of patients. Providing he number of insurances, such as benefits, has been increased so that ordinary people can choose treatment and take advantage of available medicines and treatments to improve their quality of life. In developing countries such as China and India, the government has launched several programs and initiatives to raise awareness about the disease. This has greatly increased the demand for breast cancer diagnosis and disease management therapies. Increasing mergers and acquisitions between pharmaceutical companies and government agencies are among the main trends in the Middle East and Africa breast cancer market.

Rates of new breast cancer cases have risen 0.6% per year from 2010-2019, and death rates have risen an average of 1.7% per year for the same time frame. As the breast cancer patient rate is increasing, the use of treatments and advanced technologies for the diagnosis of cancer will increase, which is an opportunity for market growth.

Challenge

  • Lack of diagnostic infrastructure

Non-communicable diseases such as breast cancer and other types of cancer have now been recognized by the United Nations and WHO as a major public health crisis. Cancer is the biggest part of this problem, and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approach and outcomes between high income countries and low and middle income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps, and lack of awareness among the lay and medical community.

Moreover, compared to early diagnosis, cancer screening is a separate and more complex public health strategy that requires additional resources, infrastructure and coordination. Rural, developing and low income countries in the different regions does not have enough infrastructure to maintain with the new kits and fro the sample storage as well. These countries need diagnostic infrastructure to ensure the early detection and rapid, accurate diagnosis of the disease.

Post-COVID-19 Impact on Middle East and Africa Breast Cancer Diagnostics Market

The COVID-19 pandemic has caused disruptions in elective health services related to breast screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of breast cancer, exacerbating existing health inequalities.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the market.

Recent Developments

  • In November 2022, Koninklijke Philips N.V., announced the Middle East and Africa launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped company to expand its product portfolio.
  • In November 2022, Siemens Healthineers and Atrium Health, a leading not-for-profit healthcare provider known for leading pediatric, cancer and cardiac care programs, have announced a multi-year value partnership1. This strategic agreement focuses on improving access to care in Atrium Health's service area in the southeastern United States, improving health equity and increasing economic mobility. Atrium Health is acquiring more than $140 million in equipment and devices from Siemens Healthineers, including advanced imaging technology, radiation oncology and precision endovascular robotics. This has helped the company to expand their business.

Middle East and Africa Breast Cancer Diagnostics Market Scope

Middle East and Africa breast cancer diagnostics market is segmented into test type, type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE

  • IMAGING
  • BIOPSY
  • GENOMIC TEST
  • BLOOD TEST
  • OTHERS

On the basis of test type, the Middle East and Africa breast cancer diagnostic market is segmented into imaging, biopsy, genomic test, blood tests and others.

MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE

  • DUCTAL CARCINOMA IN SITU
  • INVASIVE DUCTAL CARCINOMA
  • INFLAMMATORY BREAST CANCER
  • METASTATIC BREAST CANCER

On the basis of type, the Middle East and Africa breast cancer diagnostic market is segmented into ductal in situ carcinoma, invasive ductal carcinoma, inflammatory breast cancer, and metastatic breast cancer.

MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER

  • HOSPITALS
  • CLINICS
  • RESEARCH & ACADEMIC INSTITUTES
  • DIAGNOSTIC CENTERS
  • OTHERS

On the basis of end user, the Middle East and Africa breast cancer diagnostic market is segmented into hospitals, clinics, research and academic institutes, diagnostic centers and others.

MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

  • DIRECT TENDER
  • RETAIL SALES
  • OTHERS

On the basis of distribution channel, the Middle East and Africa breast cancer diagnostic market is segmented into direct tender, retail sales and others.

乳がん診断市場

Middle East and Africa Breast Cancer Diagnostics Market Regional Analysis/Insights

中東およびアフリカの乳がん診断市場が分析され、検査タイプ、種類、エンドユーザー、流通チャネルに関する市場規模の情報が提供されます。

この市場レポートでカバーされている国は、南アフリカ、サウジアラビア、UAE、エジプト、イスラエル、その他の中東およびアフリカです。

2023年には、乳がんの研究開発への投資の増加により市場の成長が促進されることが期待され、エジプトが中東およびアフリカ市場を独占することになります。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、中東およびアフリカのブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、および販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。

競争環境と中東・アフリカの乳がん診断市場シェア分析

中東およびアフリカの乳がん診断市場の競争状況では、競合他社ごとに詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、中東およびアフリカの乳がん診断市場への会社の重点にのみ関連しています。

中東およびアフリカの乳がん診断市場で活動している主要企業には、F-Hoffmann La Roche Ltd.、Siemens Healthcare GmbH、General Electric、Koninklijke Philips NV、FUJIFILM Corporation、Abbott、Hologic, Inc.、OncoStem、Provista Diagnostics、Thermo Fisher Scientific Inc.、Myriad Genetics, Inc.、Illumina, Inc.、Bio-Rad Laboratories, Inc.、BD、NanoString.、Cepheid、BIOMÉRIEUX、Exact Sciences Corporation、Biocept, Inc.、Abacus ALS などがあります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 TEST TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

5 EPIDEMIOLOGY

6 INDUSTRIAL INSIGHTS

7 REGULATORY FRAMEWORK

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH

8.1.2 INCREASING PREVALENCE OF BREAST CANCER

8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH

8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER

8.2 RESTRAINTS

8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS

8.2.2 HIGH COST OF THE IMAGING SYSTEMS

8.3 OPPORTUNITIES

8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT

8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS

8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER

8.4 CHALLENGES

8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE

8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER

9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE

9.1 OVERVIEW

9.2 IMAGING

9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES

9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)

9.2.1.2 ANALOG MAMMOGRAPHY

9.2.1.3 3D BREAST TOMOSYNTHESIS

9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)

9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)

9.2.1.6 POSITRON EMISSION MAMMOGRAPHY

9.2.1.7 OTHERS

9.2.2 NON-IONIZING IMAGING TECHNOLOGIES

9.2.2.1 OPTICAL IMAGING

9.2.2.2 BREAST ULTRASOUND

9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)

9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)

9.2.2.5 BREAST THERMOGRAPHY

9.2.3 BIOPSY

9.2.3.1 SURGICAL BIOPSY

9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY

9.2.3.3 CORE NEEDLE BIOPSY

9.2.3.4 IMAGE-GUIDED BIOPSY

9.2.3.5 SENTINEL LYMPH NODE BIOPSY

9.2.4 GENOMIC TEST

9.2.4.1 MOLECULAR TESTING

9.2.4.1.1 PD-L1

9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR)

9.2.4.1.3 NTRK GENE FUSIONS

9.2.4.1.4 PI3KCA GENE MUTATION

9.2.4.2 MAMMAPRINT

9.2.4.3 ONCOTYPE DX

9.2.4.4 OTHERS

9.3 BLOOD TEST

9.4 OTHERS

10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE

10.1 OVERVIEW

10.2 INVASIVE DUCTAL CARCINOMA

10.3 DUCTAL CARCINOMA IN SITU

10.4 INFLAMMATORY BREAST CANCER

10.5 METASTATIC BREAST CANCER

11 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 DIAGNOSTICS CENTERS

11.4 CLINICS

11.5 RESEARCH & ACADEMIC INSTITUTES

11.6 OTHERS

12 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 EGYPT

13.1.2 SOUTH AFRICA

13.1.3 ISRAEL

13.1.4 SAUDI ARABIA

13.1.5 UAE

13.1.6 REST OF MIDDLE EAST AND AFRICA

14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 HOLOGIC, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 SIEMENS HEALTHCARE GMBH

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 F. HOFFMANN- LA ROCHE LTD

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 KONINKLIJKE PHILIPS N.V.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 ABBOTT

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENTS

16.6 ABACUS ALS

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 BD

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 COMPANY SHARE ANALYSIS

16.7.4 PRODUCT PORTFOLIO

16.7.5 RECENT DEVELOPMENTS

16.8 BIOCEPT, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 BIOMÉRIEUX

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 BIO-RAD LABORATORIES, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 CEPHEID

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 EXACT SCIENCES CORPORATION

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 COMPANY SHARE ANALYSIS

16.12.4 PRODUCT PORTFOLIO

16.12.5 RECENT DEVELOPMENTS

16.13 FUJIFILM CORPORATION

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 GENERAL ELECTRIC

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 ILLUMINA, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 MYRIAD GENETICS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 NANOSTRING.

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENT

16.17.5 RECENT DEVELOPMENT

16.18 ONCOSTEM.

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 PROVISTA DIAGNOSTICS.

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 THERMO FISHER SCIENTIFIC INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 REVENUE ANALYSIS

16.20.3 PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表のリスト

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020)

TABLE 2 MORTALITY RATE OF BREAST CANCER (2020)

TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER

TABLE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 9 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 11 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 14 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 17 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 19 MIDDLE EAST & AFRICA BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 41 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 43 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 45 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 47 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 49 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 52 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 53 EGYPT IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 54 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 55 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 56 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 57 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 58 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 59 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 60 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 61 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 62 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 63 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 65 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 66 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 67 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 68 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 69 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 70 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 71 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 72 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 73 SOUTH AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 76 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 77 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 78 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 79 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 80 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 81 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 82 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 83 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 84 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 85 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 86 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 88 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 89 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 90 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 91 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 92 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 93 ISRAEL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 96 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 97 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 99 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 100 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 101 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 102 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 103 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 104 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 105 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 106 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 107 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 108 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 109 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 110 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 113 SAUDI ARABIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 114 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 115 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 116 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 117 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 118 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 119 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 120 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 121 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 122 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 123 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 124 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 125 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 126 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 128 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 129 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 130 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 131 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 132 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 133 UAE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 134 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 135 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 136 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 137 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 138 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 139 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 140 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 141 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 142 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 143 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 144 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 145 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 146 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 147 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP

TABLE 148 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)

TABLE 149 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 150 UAE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 151 UAE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 152 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

図表一覧

FIGURE 1 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET

FIGURE 14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022

FIGURE 15 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022

FIGURE 19 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022

FIGURE 23 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022

FIGURE 27 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 31 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 32 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 33 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 34 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 35 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Middle East and Africa Breast Cancer Diagnostics Market is projected to grow at a CAGR of 7.1% during the forecast period by 2030.
The future market value of the Middle East and Africa Breast Cancer Diagnostics Market is expected to reach USD 405.56 million by 2030.
The major players in the Middle East and Africa Breast Cancer Diagnostics Market are The major companies which are dealing in the market are F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., FUJIFILM Corporation, Abbott, Hologic, Inc., etc.
The countries covered in the Middle East and Africa Breast Cancer Diagnostics Market are South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa.
a